BRPI0418866A - métodos para solubilizar o latanoprost e para preparar uma solução oftálmica aquosa de latanoprost e solução resultante - Google Patents
métodos para solubilizar o latanoprost e para preparar uma solução oftálmica aquosa de latanoprost e solução resultanteInfo
- Publication number
- BRPI0418866A BRPI0418866A BRPI0418866-7A BRPI0418866A BRPI0418866A BR PI0418866 A BRPI0418866 A BR PI0418866A BR PI0418866 A BRPI0418866 A BR PI0418866A BR PI0418866 A BRPI0418866 A BR PI0418866A
- Authority
- BR
- Brazil
- Prior art keywords
- latanoprost
- ophthalmic solution
- solubilizing
- preparing
- solution
- Prior art date
Links
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 title abstract 5
- 229960001160 latanoprost Drugs 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 5
- 230000003381 solubilizing effect Effects 0.000 title abstract 3
- 229940110775 latanoprost ophthalmic solution Drugs 0.000 title abstract 2
- 239000000243 solution Substances 0.000 title abstract 2
- 229940054534 ophthalmic solution Drugs 0.000 abstract 3
- 239000002997 ophthalmic solution Substances 0.000 abstract 3
- 239000000126 substance Substances 0.000 abstract 2
- IYGXEHDCSOYNKY-RZHHZEQLSA-N Dinoprost tromethamine Chemical compound OCC(N)(CO)CO.CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O IYGXEHDCSOYNKY-RZHHZEQLSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
MéTODOS PARA SOLUBILIZAR O LATANOPROST E PARA PREPARAR UMA SOLUçãO OFTáLMICA AQUOSA DE LATANOPROST E SOLUçãO RESULTANTE. A invenção refere-se a um método para solubilizar um agente ativo análogo da prostaglandina F2<244>, tal como latanoprost, e um método para preparar uma solução oftálmica aquosa a partir do latanoprost solubilizado para o tratamento de diversas afecções oculares. A presente invenção refere-se, além disso, a uma solução oftálmica aquosa que resulta do referido método, a qual se caracteriza por sua estabilidade química à temperatura ambiente, segurança, inocuidade e eficácia no tratamento do paciente. A nova solução oftálmica aquosa distingue-se porque seu valor farmacêutico radica no manejo de um veículo de fácil acesso que não somente permite a solubilidade do latanoprost, mas também favorece sua estabilidade química e uma maior tolerância do paciente à sua aplicação para o tratamento de seu padecimento.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/MX2004/000034 WO2005115401A1 (es) | 2004-05-26 | 2004-05-26 | Un método para preparar una solución oftálmica de latanoprost y solución resultante |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0418866A true BRPI0418866A (pt) | 2007-11-20 |
Family
ID=35450648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0418866-7A BRPI0418866A (pt) | 2004-05-26 | 2004-05-26 | métodos para solubilizar o latanoprost e para preparar uma solução oftálmica aquosa de latanoprost e solução resultante |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US8293789B2 (pt) |
| EP (1) | EP1759702B1 (pt) |
| AR (1) | AR049113A1 (pt) |
| AT (1) | ATE419854T1 (pt) |
| BR (1) | BRPI0418866A (pt) |
| DE (1) | DE602004018990D1 (pt) |
| DK (1) | DK1759702T3 (pt) |
| ES (1) | ES2320770T3 (pt) |
| PL (1) | PL1759702T3 (pt) |
| PT (1) | PT1759702E (pt) |
| SI (1) | SI1759702T1 (pt) |
| WO (1) | WO2005115401A1 (pt) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8609634B2 (en) * | 2007-05-16 | 2013-12-17 | Mcneil-Ppc, Inc. | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods |
| US9579341B2 (en) | 2007-05-16 | 2017-02-28 | Johnson & Johnson Consumer Inc. | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods |
| US20100130444A1 (en) * | 2007-07-11 | 2010-05-27 | El Mustapha Belgsir | Complexes of prostaglandin derivatives and monosubstituted, charged beta-cyclodextrins |
| ES2667945T3 (es) | 2007-10-08 | 2018-05-16 | Aurinia Pharmaceuticals Inc. | Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR |
| US8455547B2 (en) | 2008-02-05 | 2013-06-04 | Allergan, Inc. | Substituted cyclopentanes having prostaglandin activity |
| ITRM20080182A1 (it) * | 2008-04-07 | 2009-10-08 | Medivis S R L | Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma. |
| US9481856B2 (en) * | 2008-06-09 | 2016-11-01 | Bausch & Lomb Incorporated | Pharmaceutical formulations comprising stabilized polysaccharides and source of hydrogen peroxide |
| US10463677B2 (en) * | 2008-11-07 | 2019-11-05 | Cydex Pharmaceuticals, Inc. | Composition containing sulfoalkyl ether cyclodextrin and latanoprost |
| EP2393490A1 (en) * | 2009-02-04 | 2011-12-14 | INSERM - Institut National de la Santé et de la Recherche Médicale | Taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration |
| DE102009021372A1 (de) * | 2009-05-14 | 2010-11-18 | Ursapharm Arzneimittel Gmbh | Phosphatfreie pharmazeutische Zusammensetzung zur Glaukombehandlung |
| EP2440185B1 (en) * | 2009-06-09 | 2015-04-08 | Aurinia Pharmaceuticals Inc. | Topical drug delivery systems for ophthalmic use |
| US8952051B2 (en) * | 2009-11-05 | 2015-02-10 | Allergan, Inc. | Ophthalmic formulations containing substituted gamma lactams and methods for use thereof |
| US20110136872A1 (en) * | 2009-12-09 | 2011-06-09 | Burk Robert M | Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof |
| US10272040B2 (en) | 2010-08-12 | 2019-04-30 | Nanyang Technological University | Liposomal formulation for ocular drug delivery |
| DE102011108948A1 (de) * | 2011-07-29 | 2013-01-31 | Achim Göpferich | Wässrige, kolloidale Lösungen von lipophilen Substanzen,insbesondere Arzneistofflösungen |
| EP2567689A1 (en) * | 2011-09-12 | 2013-03-13 | Visiotact Pharma | Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid |
| US9956195B2 (en) | 2014-01-07 | 2018-05-01 | Nanyang Technological University | Stable liposomal formulations for ocular drug delivery |
| ES2669446B1 (es) * | 2016-11-24 | 2019-03-13 | Saiz Manuel Munoz | Producto oftálmico |
| US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
| GR1009419B (el) * | 2017-11-07 | 2018-12-14 | Φαρματεν Αβεε | Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου |
| JP2022519580A (ja) * | 2019-02-06 | 2022-03-24 | ティアークリアー コープ． | 複合体化剤を含む眼科用製剤から防腐剤を除去するためのシステムおよび方法 |
| EP4331683A3 (en) | 2019-08-07 | 2024-08-07 | Aneira Pharma, Inc. | Methods and compositions for the treatment of hair loss |
| US12539302B2 (en) | 2019-08-07 | 2026-02-03 | Aneira Pharma, Inc. | Methods and compositions for the treatment of hair loss |
| PL4167965T3 (pl) * | 2020-06-21 | 2025-03-24 | i.com medical GmbH | Zastosowanie kwasu hialuronowego o wysokiej masie cząsteczkowej jako nośnika do transportu do oczu |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU665287B2 (en) * | 1992-12-21 | 1995-12-21 | Alcon Laboratories, Inc. | Prostaglandin combinations in glaucoma therapy |
| US5631287A (en) | 1994-12-22 | 1997-05-20 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
| US6646001B2 (en) | 1997-12-19 | 2003-11-11 | Alcon Manufacturing, Ltd. | Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension |
| ATE289817T1 (de) * | 1998-12-25 | 2005-03-15 | Sucampo Ag | Arzneimittelzusammenstellung zur behandlung des erhöhten augeninnendrucks oder des glaukom |
| AU2001233286B2 (en) * | 2000-02-01 | 2006-04-06 | Cayman Chemical Company, Incorporated | Internal 1,15-lactones of fluprostenol and related prostaglandin F2alpha analogs and their use in the treatment of glaucoma and intraocular hypertension |
| US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| PE20020578A1 (es) * | 2000-10-10 | 2002-08-14 | Upjohn Co | Una composicion de antibiotico topico para el tratamiento de infecciones oculares |
| US20030018079A1 (en) | 2000-11-13 | 2003-01-23 | Richardson Helene | Treatment |
-
2004
- 2004-05-26 PL PL04748557T patent/PL1759702T3/pl unknown
- 2004-05-26 DK DK04748557T patent/DK1759702T3/da active
- 2004-05-26 SI SI200431084T patent/SI1759702T1/sl unknown
- 2004-05-26 EP EP04748557A patent/EP1759702B1/en not_active Expired - Lifetime
- 2004-05-26 PT PT04748557T patent/PT1759702E/pt unknown
- 2004-05-26 US US11/597,459 patent/US8293789B2/en not_active Expired - Fee Related
- 2004-05-26 AT AT04748557T patent/ATE419854T1/de active
- 2004-05-26 DE DE602004018990T patent/DE602004018990D1/de not_active Expired - Lifetime
- 2004-05-26 ES ES04748557T patent/ES2320770T3/es not_active Expired - Lifetime
- 2004-05-26 WO PCT/MX2004/000034 patent/WO2005115401A1/es not_active Ceased
- 2004-05-26 BR BRPI0418866-7A patent/BRPI0418866A/pt not_active IP Right Cessation
-
2005
- 2005-05-24 AR ARP050102140A patent/AR049113A1/es not_active Application Discontinuation
-
2011
- 2011-01-03 US US12/983,721 patent/US20110098354A1/en not_active Abandoned
- 2011-01-03 US US12/983,736 patent/US20110105605A1/en not_active Abandoned
- 2011-01-03 US US12/983,751 patent/US20110098355A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005115401A1 (es) | 2005-12-08 |
| AR049113A1 (es) | 2006-06-28 |
| SI1759702T1 (sl) | 2009-06-30 |
| PL1759702T3 (pl) | 2009-06-30 |
| ES2320770T3 (es) | 2009-05-28 |
| US20080021101A1 (en) | 2008-01-24 |
| US20110098355A1 (en) | 2011-04-28 |
| US8293789B2 (en) | 2012-10-23 |
| US20110105605A1 (en) | 2011-05-05 |
| DE602004018990D1 (de) | 2009-02-26 |
| PT1759702E (pt) | 2009-04-13 |
| DK1759702T3 (da) | 2009-04-20 |
| EP1759702B1 (en) | 2009-01-07 |
| ATE419854T1 (de) | 2009-01-15 |
| EP1759702A1 (en) | 2007-03-07 |
| US20110098354A1 (en) | 2011-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0418866A (pt) | métodos para solubilizar o latanoprost e para preparar uma solução oftálmica aquosa de latanoprost e solução resultante | |
| BRPI0513849A (pt) | implante ocular fabricado por um processo de extrusão dupla | |
| BRPI0819081A8 (pt) | Formulação oftálmica aquosa, processo para preparar a mesma, e, método para inibir, tratar ou prevenir doenças oculares e doença ou condição relacionada, em um paciente em necessidade de tal tratamento | |
| ES2052784T3 (es) | Procedimiento para la produccion de una composicion terapeutica administrable localmente para una enfermedad inflamatoria. | |
| BRPI0210707B8 (pt) | composição de solução para administração tópica no tratamento de distúrbios alérgicos ou inflamatórios do olho e do nariz e seu método de preparação | |
| BR0317774A (pt) | Uso de rimexolona no tratamento de olho seco | |
| ECSP12012037A (es) | Composiciones oftálmicas no irritantes de iodopovidona | |
| CR10169A (es) | "uso de derivados de sulfamida heterociclica benzo-fusionada para disminuir lipidos y disminuir niveles de glucosa en la sangre" | |
| BRPI0111591B8 (pt) | composto, composição farmacêutica, e, usos de um composto | |
| BR0209327A (pt) | Composição para tratamento de constipação induzida por drogas | |
| EA201300314A1 (ru) | Композиции и лекарственное средство для лечения глазных болезней, устройство, содержащее композиции и лекарственное средство | |
| RU2008127882A (ru) | Лечение пищевода барретта | |
| Kringelholt et al. | Dual effect of prostaglandins on isolated intraocular porcine ciliary arteries | |
| BR0318395A (pt) | método para preparar uma solução aquosa de meloxicam e a solução aquosa resultante | |
| BR112022017509A2 (pt) | Composições terapêuticas de liberação prolongada estáveis em solventes polares apróticos e métodos de fabricação das mesmas | |
| RU2008102249A (ru) | Профилактический или терапевтичесский агент для корнеального /конъюнктивального заболевания | |
| RU2008110945A (ru) | N-оксиды как пролекарства производных пиперазина и пиперидина | |
| TWI712429B (zh) | 水性醫藥組成物 | |
| Huang et al. | Nanocatalysts as fast and powerful medical intervention: Bridging cochlear implant therapies and advanced modelling using Hidden Markov Models (HMMs) for effective treatment of inner ear infections | |
| RU2002104498A (ru) | Применение тозилхлорамидов для лечения заболеваний кожи, слизистой оболочки, органов и тканей | |
| BR0209601A (pt) | Método para o tratamento da hipertensão ocular e do glaucoma | |
| BR0212167A (pt) | Forma de dosagem oral de liberação prolongada, uso da mesma, método para a prevenção e/ou tratamento de distúrbios e perturbações médicas, e, processo para a fabricação de uma forma de dosagem de liberação prolongada | |
| CA2901208A1 (en) | Topical ocular analgesic agents | |
| JP2012006962A (ja) | 眼科用組成物 | |
| US20130102661A1 (en) | Irrigation solutions containing ascorbic acid or its salts and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: PARA: INT. CL. A61K 31/5575; A61P 27/02, 27/06 Ipc: A61K 31/5575 (2011.01), A61P 27/02 (2011.01), A61P |
|
| B08L | Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A E 10A ANUIDADES. |
|
| B08I | Publication cancelled [chapter 8.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2257 DE 08/04/2014 POR TER SIDO INDEVIDA. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A E 16A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |